









Markets
/
Stocks
/
nasdaq-ensc
/

Ensysce Biosciences Inc

ENSC

2.130USD

+0.030+1.43%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

5.10MMarket Cap

LossP/E TTM



Ensysce Biosciences Inc

2.130

+0.030+1.43%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a . Despite an average stock market performance, the company shows strong fundamentals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

282 / 506

Overall Ranking

475 / 4720

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 0 analysts

Current Rating

26.225

Target Price

+1148.81%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical company. The Company develops solutions for severe pain relief while reducing the potential for opioid misuse, abuse, and overdose. Its pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the Trypsin Activated Abuse Protection (TAAP) platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant (MPAR) platform. The TAAP platform is designed to improve the care of patients with chronic pain while reducing the human and economic costs associated with prescription opioid drug abuse. The MPAR platform, when combined with its TAAP prodrugs, is designed to seek to prevent abuse of prescription drugs but also to reduce overdose occurrences. Additionally, nafamostat di-mesylate (nafamostat), which is an ingredient in its overdose protection combination products, is also being developed for the intended purpose of treating infection and pulmonary lung diseases.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 106.47% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 5.21M.

Undervalued

The company’s latest PE is -0.61, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 374.03K shares, increasing 16.88% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 2.38K shares of this stock.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 8.37, which is higher than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 1.37M, representing a year-over-year increase of 654.38%, while its net profit experienced a year-over-year increase of 11.91%.

Score

Industry at a Glance

Previous score

8.37

Change



Financials

8.31

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

8.43

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

7.79

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.30

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -0.60, which is -65.09% below the recent high of -0.21 and 0.00% above the recent low of -0.60.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 282/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

There is no earnings forecast score for this company; the Biotechnology & Medical Research industry's average is 8.03. The average price target for Ensysce Biosciences Inc is 26.23, with a high of 34.00 and a low of 18.45.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

No Data

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 1.19, which is lower than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 2.21 and the support level at 2.00, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

1.19

Change

-0.01

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(4)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.005

Neutral

RSI(14)

52.189

Neutral

STOCH(KDJ)(9,3,3)

55.345

Neutral

ATR(14)

0.098

High Vlolatility

CCI(14)

20.533

Neutral

Williams %R

43.005

Buy

TRIX(12,20)

0.009

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

2.102

Buy

MA10

2.111

Buy

MA20

2.104

Buy

MA50

2.125

Buy

MA100

2.199

Sell

MA200

3.861

Sell

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 15.78%, representing a quarter-over-quarter increase of 2.91%. The largest institutional shareholder is The Vanguard, holding a total of 2.38K shares, representing 0.08% of shares outstanding, with 1.00% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Perceptive Advisors LLC

86.67K

Adage Capital Management, L.P.

74.71K

+49.42%

Gower (Robert G)

8.13K

FNY Investment Advisers LLC

3.00K

Tower Research Capital LLC

441.00

+0.68%

Benton (Andrew K. J.D.)

1.33K

Chang (William H C)

722.00

-64.85%

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 2.99, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 1.08. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.